News & Updates
Filter by Specialty:
High marks for modified-release oral PDE4 inhibitor in moderate-to-severe psoriasis
The modified-release formulation of novel oral phosphodiesterase-4 (PDE4) inhibitor orismilast shows therapeutic potential in adults with moderate-to-severe psoriasis, with high rates of clinical response as compared with placebo, according to data from the phase IIb IASOS trial presented at AAD 2023.
High marks for modified-release oral PDE4 inhibitor in moderate-to-severe psoriasis
05 Apr 2023
Oral JAK inhibitor makes headway in alopecia areata
Patients with severe alopecia areata (patchy baldness) had a dramatic hair regrowth, without serious adverse events, when treated with an investigational Janus kinase (JAK) inhibitor in the phase III THRIVE-AA2 study presented at AAD 2023.
Oral JAK inhibitor makes headway in alopecia areata
05 Apr 2023
QUARTZ3 data make a case for using ivarmacitinib in atopic dermatitis
Treatment with the oral highly selective JAK1 inhibitor ivarmacitinib appears to help reduce disease activity in patients with moderate-to-severe atopic dermatitis (AD), with up to 42 percent of them having complete or near-complete clearance of involved skin areas, according to the results of the pivotal phase III QUARTZ3 trial presented at AAD 2023.
QUARTZ3 data make a case for using ivarmacitinib in atopic dermatitis
04 Apr 2023
Online telepharmacy service delivers despite pandemic-related restrictions
A free online telepharmacy service, developed in the Philippines during the COVID-19 pandemic, may be used to provide and simplify medication information as part of primary care, reports a study.